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Abstract
Background: Western drugs have achieved great successes in CVDs treatment. However, they may lead to some
side effects and drug resistance. On the other hand, more and more studies found that Traditional Chinese herbs
have efficient therapeutic effects for CVDs, while their therapeutic mechanism is still not very clear. It may be a
good view towards molecules, targets and network to decipher whether difference exists between anti-CVD
western drugs and Chinese herbal ingredients.
Results: Anti-CVD western drugs and Chinese herbal ingredients, as well as their targets were thoroughly collected
in this work. The similarities and the differences between the herbal ingredients and the western drugs were
deeply explored based on three target-based perspectives including biochemical property, regulated pathway and
disease network. The biological function of herbal ingredients’ targets is more complex than that of the western
drugs’ targets. The signal transduction and immune system associated signaling pathways, apoptosis associated
pathways may be the most important pathway for herbal ingredients, however the western drugs incline to
regulate vascular smooth muscle contraction associated pathways. Chinese herbal ingredients prefer to regulate
the downstream proteins of apoptosis associated pathway; while the western drugs incline to regulate the
upstream proteins of VECC (Vascular Epidermal Cells Contraction) related pathways.
Conclusion: In summary, the characteristics identified in this study would be valuable for designing new network-
based multi-target CVD drugs or vaccine adjuvants.
Background
According to the statistics of The World Health Organiza-
tion (WHO), CVDs are the world’s largest killers of human
health, since these disorders lead to 17.1 million deaths per
year and the death number is still rising [1]. Cardiovascular
diseases (CVDs) is the general term that describes a num-
ber of circulatory system diseases, which mainly include
ischemic heart disease, hypertension, cardiac arrhythmias,
stroke, myocardial infarction, coronary artery disease,
hypertrophic cardiomyopathy, hyperlipidemia, etc [2,3].
Both genetic abnormalities and environmental factors play
important roles in CVDs development. Their pathological
mechanisms often refer to many complex physiological
processes, such as inflammation [3], apoptosis [4,5], oxida-
tive stress [6], and lipid metabolism [7].
There have been various anti-CVD drugs approved by
US FDA. One of the most-used examples is the statins.
They have reduced the mortality and morbidity from
atherosclerotic heart disease by about 30%, but the
remaining 70% CVDs still need novel therapies [8]. In
recent years, with the development of genomics [9] and
proteomics [10], a large number of associated genomic
and gene regulation data make it possible to develop
new drugs for CVDs. Bezafibrate [11], Lisinopril [12],
Quinapril [13] and so on, have been developed as new
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drugs of CVDs. Although western drugs have achieved
great successes in CVDs treatment, they may lead to
serious side effects [14] and drug resistance [15].
On the other hand, more and more studies found that
Chinese herbs have efficient therapeutic effect for CVDs,
such as Danshen Pian [16,17], Yin Xing Ye Pian [16,18],
Shengmai Yin [16] and Xinning Pian [16]. For instance,
Danshen has a range of potentially beneficial effects,
including causing coronary vasodilatation, suppressing
the formation of thromboxane, and inhibiting platelet
adhesion and aggregation [19]. G. biloba extract (GBE)
was found to decrease capillary permeability, inhibit pla-
telet-activating factors, and decrease vascular resistance
[20]. Herbal ingredients have been expected as a potential
drug like database [21]. In addition, increased research
has been carried out in search of new adjuvant candidates
from traditional Chinese medicinal herbs [22,23].
Although great promise has been shown for Chinese
herbs, their therapeutic mechanism is still not very clear.
Before demystify the mechanism of anti-CVD Chinese
herbs, researchers want to know whether there is any dif-
ference between herbal ingredients and western drugs? It
may be a good view towards molecules and their targets
to decipher these questions. In this study, herbal ingredi-
ents (active compounds in herb which have been
reported with anti-CVD effects) and western drugs (FDA-
approved drugs with anti-CVD effectiveness) have been
comprehensively collected. Their corresponding target
proteins were retrieved from DrugBank [24] and HIT
[25]. Then, the similarities and the differences of molecu-
lar mechanism between those herbal ingredients and wes-
tern drugs were probed from 3 target-based perspectives:




Molecules, targets and related diseases
Western drugs whose first letter of ATC code is “C” and
their associated targets were downloaded from DrugBank.
The keywords such as: “Hypertension”, “Hyperlipidemia”,
“Coronary heart disease”, “Stroke”, “Myocardial infarc-
tion”, “Angina”, “Atherosclerosis”, “Cardiomyopathy”,
“Heart failure” and “Thrombosis” have been used to search
anti-CVD herbs in Chinese Pharmacopoeia [16]. The
ingredients of anti-CVD herbs and their corresponding
targets were extracted from HIT [25]. Two kinds of ingre-
dients’ targets have been collected from HIT: direct targets
and indirect targets.
Targets and associated diseases were collected from
Therapeutic Target Database (TTD) [26]. As targets are
under different stages of study, they have been classified
into three categories in TTD: Successful targets, Clinical
trial targets and Research targets.
Protein biochemical family, structure domain and cell
location
Protein Biochemical family data was downloaded from
UniProtKB [27]. Protein structure domain data was
obtained from Pfam [28]. Protein cell location data was
collected from The Gene Ontology (GO) [29]. GO pro-
vides an ontology of defined terms representing gene
product properties, cell location information for the tar-
gets was extracted from Cellular component item.
Protein transcription factor
TRANSFAC database records eukaryotic transcription
regulating DNA sequence elements and the transcription
factors binding to and acting through them [30]. Informa-
tion of transcription factor was retrieved from TRANS-
FAC, 618 transcription factors have been included in
TRANSFAC.
Network construction and analysis
Construction of target-pathway network and compound-
pathway network
Firstly, target proteins of herbal ingredients and western
drugs were mapped onto KEGG pathways [31] respec-
tively. Targets were considered to participate in a specific
pathway if they appear in the pathway. Through regulat-
ing those targets, western drugs or herbal ingredients act
on pathways. A bipartite graph was constructed by linked
pathways and targets, which represents the association of
targets and pathways [32]. In the same way, the com-
pound (a compound means an herbal ingredient or a
western drug)-pathway network was generated.
Degree distribution of network
In network, the number of edges linked to a node was
defined as degree. The degree distribution f(x) of network
is the frequency of nodes with degree x. It is reported that
degree distribution of the majority of real world networks
especially biological networks obey power law. In another
word, the majority of nodes in network would only influ-
ence few nodes, while few nodes would affect a lot of
nodes and play important roles in whole network [32,33].
Pathway enrichment for targets of herbal ingredients and
western drugs
Pathway enrichment analysis [34] has been applied to
query whether a compound regulate a pathway by chance
or not. Fisher’s exact test was used. A significance level
with a Pvalue less than 0.01 means the compound would
regulate the pathway at a high probability [32].
Construction of disease network
In previous reported studies, inflammation, apoptosis and
Ca2 + channel caused vascular epidermal cells contraction
disorder were the main pathogenesis for cardiovascular
diseases. Firstly, two CVDs local networks were
constructed: the CVDs-Apoptosis-Network and the CVDs-
VECC (vascular epidermal cells contraction)-Network.
Secondly, the whole-CVDs-network was built which
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integrates CVDs associated pathways in KEGG, BioCarta
[35] and Therapeutically Relevant Multiple Pathways
(TRMP) [36].
Results and discussions
Targets of herbal ingredients and western drugs
184 FDA-approved anti-CVD western drugs as well as
their 204 protein targets were collected from DrugBank.
40 anti-CVD herbs were collected in the Chinese Phar-
macopoeia as well. For these anti-CVD herbs, 172 herbal
ingredients and 862 protein targets were identified from
the HIT, among which 118 were direct targets.
Targets of herbal ingredients and western drugs were
mapped to TTD [37] (Table 1). Targets in TTD have
been mainly grouped into three categories: Successful
targets, Clinical trial targets and Research targets.
Among the collected western drug’s targets, 81(39.7%)
are successful targets, 15(7.4%) are clinical trial targets,
29(14.2%) are research targets and 2(1.7%) are discontin-
ued targets. For the direct targets of herbal ingredients,
32(27.1%) are successful targets, 10(8.5%) are clinical
trial targets, 32(27.1%) are research targets and 3(2.5%)
are discontinued targets. Additionally, among all targets
(including direct and indirect targets) of herbal ingredi-
ents, 84(9.7%) are successful targets, 88(10.2%) are clini-
cal trial targets, 180(20.9%) are research targets and 14
(1.6%) are discontinued targets. Totally, 62.3% targets of
western drugs, 65.3% of direct targets herbal ingredients
and 41.5% all targets of herbal ingredients are recorded
in TTD. Herbal ingredients’ direct targets were more
similar to western drugs’ targets than all targets of her-
bal ingredients. To better compare herbal ingredients
and western drugs, the bias of their target number and
target type should be excluded. Only direct targets of
herbal ingredients were used in the following study.
D/t values (the average value for the number of asso-
ciated diseases for each target) were calculated for herbal
ingredients’ and western drugs’ targets (Table 2). Herbal
ingredients showed higher d/t value than western drugs in
each category. The average number of herbal ingredients’
targets associated diseases is higher than that of western
ones. It implies that herbal ingredients’ targets may associ-
ate with more diseases than the targets of western drugs.
To some extent, the number of targets associated-
diseases depends on the complexity of the biological
function of the target. Since the domain types of pro-
tein targets were often used to measure the biological
function complexity, distribution of the number of
structure domain for targets of western drugs and
herbal ingredients were obtained by Pfam (Figure 1a).
The numbers of structure domain of targets from
herbal ingredients tends to be more than those of
western drugs. It indicates that the biological function
of the herbal ingredients’ targets is more complex than
that of the western drugs. This is also consistent with
the observation from the d/t value analysis. In another
word, herbal ingredients’ targets would link to more
diseases and prefer to participate in more complicated
biological functions.
As shown in Additional file 1, figure S1, 27% of western
drugs bind different subtypes of the same type of protein
targets such as inhibitors of calcium ion channel etc. The
other 28% of western drugs regulate different targets in
the same biological process. That is to say, besides one-
target-drugs, most targets of multi-targets western drugs
either belong to the same protein type or participate in
the same biological process. This might hint why western
drugs are often used for a certain disorder.
Protein targets were classified into certain families:
enzymes, channels and transporters, receptors, factors
and regulators, structure proteins, binding proteins and
others [38]. As seen from Figure 1b, targets of herbal
ingredients were enriched in enzymes, factors and regula-
tors. Western drugs’ targets were enriched in receptors,
channels and transporters. To some extent, the biochem-
ical family of proteins depends on the cellular location of
the proteins. The cellular locations of targets from herbal
ingredients and western drugs were extracted from GO
(Figure 1c). Targets of herbal ingredients preferred to
locate in cytoplasm and nucleus, while western drugs
preferred to locate in plasma membrane. As we know,
enzymes, factors and regulators often locate in cytoplasm
and nucleus, channels and transporters, receptors usually
locate in plasma membrane. The results in cellular loca-
tion accorded with the bio-chemical family analysis.
Therefore, herbal ingredients may prefer to target
Table 1 Protein targets of herbal ingredients and western drugs in TTD.
Class western drugs-targets(204) herbal ingredients -direct targets(118) herbal ingredients -all targets(862)
number of targets Percentage number of targets Percentage number of targets Percentage
Successful targets 81 39.7% 32 27.1% 84 9.7%
Clinical trial targets 15 7.4% 10 8.5% 88 10.2%
Research targets 29 14.2% 32 27.1% 180 20.9%
Discontinued targets 2 1.7% 3 2.5% 14 1.6%
Sum of targets in TTD 127 62.3% 77 65.3% 358 41.5%
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enzymes, factors and regulators in cytoplasm and
nucleus, while western drugs may prefer to target chan-
nels and transporters, receptors in plasma membrane.
11 targets of 118 herbal ingredients’ direct targets
were TFs (transcript factor), while only 10 out of 204
western drugs targets were TFs (Table 3). Fisher’s exact
test was used to quantitatively measure which kind of
targets is more enriched with TFs. The P-value of herbal
ingredients is less than 0.01, however western drugs’ is
greater than 0.05. It implies that herbal ingredients pre-
fer to target TFs than western drugs.
As summarized from the above protein family analysis,
cellular location analysis, and the TF enrichment analy-
sis, the targets of western drugs are enriched in channels
and transporters, receptors, and they tend to locate on
the plasma membrane, which agrees with the common
sense about western drug discovery. On the other hand,
the targets of herbal ingredients are enriched in
enzymes, factors and regulators, and they prefer to
locate in cytoplasm and nucleus. This suggests that her-
bal ingredients may provide new insights for CVDs ther-
apy. In addition, as the herbal ingredients’ targets locate
in cytoplasm and nucleus, this may meet difficulties in
exploring herbal ingredients’ mechanism.
Pathways analysis
To get an overall view of the interplays between herbal
ingredients/western drugs and KEGG PATHWAY, we
mapped all the targets of herbal ingredients and western
Figure 1 a. the domain number of herbal ingredients and western drugs targets. b. Distribution of main protein biochemical family of
herbal ingredients and western drugs. c. Distribution of subcellular location of targets.
Table 2 Drug targets related diseases from TTD.
Type of targets Number of diseases d/t
Successful target(81) 221 2.73
western drugs Clinical trial target(15) 45 3.0
Research target(29) 56 1.93
Successful target(32) 160 5.0
herbal ingredients Clinical trial target(10) 39 3.9
Research target(32) 76 2.38
(d/t represents the average value for the number of associated diseases
for each target)
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drugs onto the KEGG PATHWAY [31] respectively. It is
found that they are enriched in 65(herbal ingredients) and
35(western drugs) pathways (P-value < 0.01). However, no
matter for herbal ingredients’ or western drugs targets, at
least 33% pathways of the enriched pathways was Disease
pathway (Additional file 2, figure S2). We next mapped her-
bal ingredients and western drugs targets onto the basic
KEGG PATHWAY (without the disease pathway in KEGG
PATHWAY) respectively and found that they enriched in
35(herbal ingredients) and 25(western drugs) basic KEGG
pathways. Target-pathway network of herbal ingredients
and western drugs were illustrated in Figure 2, 3. In herbal
ingredients target-pathway network, signal transduction
pathways and immune system associated signaling path-
ways, apoptosis associated pathways interacted with quite
plenty of targets, and these pathways also showed high sig-
nificance enrichment. In western drugs target-pathway net-
work, cardiac and vascular smooth muscle contraction
associated pathways interacted with many targets.
Compound-pathway network was constructed, where a
compound and a pathway were linked each other if one
target of the compound was included in that pathway
(Figure 4, 5). The signal transduction and immune sys-
tem associated signaling pathway, apoptosis associated
pathways have a higher degree than others in herbal
ingredient-pathway network. Vascular smooth muscle
contraction associated pathways showed high degree in
drug-pathway network for western drugs.
It can be inferred from both target-pathway and com-
pound-pathway analysis that signal transduction and
immune system associated signaling pathways, apoptosis
associated pathways are always the most important path-
way of herbal ingredients, while for the western drugs,
the most important pathways are cardiac and vascular
smooth muscle contraction associated pathways. These
herbal ingredients can be exerted along with the vaccine
to elicit a faster and stronger immune response [22].
Disease network
In order to further pathway analysis, we constructed
CVDs-Apoptosis-Network and CVDs-VECC (Vascular
Epidermal Cells Contraction)-Network and CVDs-Whole-
Network. In previous studies, cellular apoptosis plays an
important role in the development of some CVDs [39],
inhibiting apoptosis was an effective way to prevent and
control heart failure [5]. The CVDs-Apoptosis-Network was
constructed (Figure 6) by integrating known apoptosis
associated pathways in the process of CVDs development.
There were many targets of herbal ingredients participated
in the network, but only two targets of western drugs acted
on it. The targets participated in CVDs-Apoptosis-Network
further indicate that herbal ingredients preferred to cure
CVDs through regulating cellular apoptosis.
Vascular Endothelial Cell Contraction (VECC) was one
of the factors for the development of some CVDs, and
some drugs had been reported to cure hypertension by
regulating vascular endothelial cell contraction associated
pathways [40]. Thus, a CVDs-VECC-Network (Figure 7)
was constructed by integrating VECC associated path-
ways in the process of CVDs development. Many of the
targets of western drugs present in the network, while
only two targets of herbal ingredients presented. This
agreed with the hint from former pathway analysis that
western drugs preferred to target cardiac and vascular
smooth muscle contraction associated pathways.
The CVDs-Whole-Network was constructed by integrat-
ing CVDs associated pathways included in KEGG and
Therapeutically Relevant Multiple Pathways (TRMP)
Database (Figure 8). Western drugs trend to target blood
proteins and membrane proteins, while herbal ingredients
only targeted one blood protein and most of its targets
located inside the cell.
The CVDs-Whole-Network and the two local networks
provide an overview that western drugs prefer to target the
upstream of CVDs, while the herbal ingredients prefer to
modulate the downstream of CVDs.
Adjuvant discussion
Use of adjuvant in the vaccine preparation is a long stand-
ing practice. Despite major advances in vaccine adjuvants,
Table 3 Transcription factor distribution for targets of
western drug and herbal ingredients

























(Fisher’s exact test P-value, herbal ingredients: 0.00108, Western drug: 0.14684)
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Figure 2 The target-pathway network of herbal ingredients (The gradient of color and size for the pathway-nodes changes according
to the enrichment (P-value) and degree: light red for pathways with big P-value, while deep red for pathways with small P-value; big
node for pathways with high degree, while small node with low degree).
Figure 3 The target-pathway network of western drugs (The gradient of color and size for the pathway-nodes changes according to
the enrichment (P-value) and degree: light red for pathways with big P-value, while deep red for pathways with small P-value; big
node for pathways with high degree, while small node with low degree).
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Figure 4 The compound-pathway network of herbal ingredients (The gradient of color and size for the pathway-nodes changes
according to the enrichment (P-value) and degree: light red for pathways with big P-value, while deep red for pathways with small P-
value; big node for pathways with high degree, while small node with low degree).
Figure 5 The compound-pathway network of western drugs (The gradient of color and size for the pathway-nodes changes according
to the enrichment (P-value) and degree: light red for pathways with big P-value, while deep red for pathways with small P-value; big
node for pathways with high degree, while small node with low degree).
Fu et al. BMC Bioinformatics 2014, 15(Suppl 4):S3
http://www.biomedcentral.com/1471-2105/15/S4/S3
Page 7 of 11
Figure 6 The CVDs-Apoptosis-Network (Different colors represent Different type of targets: the green is the targets of herbal
ingredients, and the light red is common targets for western drugs and herbal ingredients. The arrow near the rectangle represents the
activities of compounds for the protein: up means activation, down means inhibition).
Figure 7 The CVDs-VECC (Vascular Endothelial Cell Contraction)-Network (Different colors represent Different type of targets: the
yellow is the targets of western drugs, and the green is the targets of herbal ingredients. The arrow near the rectangle represents the
activities of compounds for the protein: up means activation, down means inhibition).
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vaccines seem to depend on aluminium salts. However,
these adjuvants would lead to serious adverse effects [41].
Herbal ingredients as immuno-modulator are paving its
way as a safe alternative.
From the results of pathway enrichment, herbal ingredi-
ents’ direct target significantly enriched in seven immune
system pathways, while no immune system pathway was
enriched by western drugs’ targets. For example, curcumin
(the extractive of radix curcumae) would not only regulate
interleukin 1(IL1), interleukin 6(IL6), interleukin 8(IL8),
interferon-g(IFN-g) and Transforming Growth Factor beta
(TGF-b) in T and B cell, but also target some immune
Figure 8 The CVDs-Whole-Network (Different colors represent Different type of targets: the yellow is the targets of western drugs, the
green is the targets of herbal ingredients, and the light red is common targets of western drugs and herbal ingredients. The arrow near
the rectangle represents the activities of drugs or herbal ingredients for the protein: up means activation, down means inhibition).
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proteins such as, Toll-like receptor 4(TLR4), CD80 and
CD28. Styrene (the extractive of storax) can affect IL4,
IL5, IL13 and TGF-b expression. Resveratrol (the extrac-
tive of polygonum cuspidatum) can regulate IL1, IL6, IL8,
IL10, IFN-g, TGF-b, CD80 and CD28. What’s more, gin-
seng saponins have adjuvant effects on the specific
immune responses, which due to their can promote IL1
production by pertoneal macrophages, stimulate secretion
of cytokine such as IL2, IL4, IL6, IL8, IL10, IFN-g and
TNF-a, regulate TLR4 to produce proinflammatory cyto-
kines, and affect TGF-b to enhance lymphocyte prolifera-
tion [42-45]. Therefore, those herbal ingredients could
regulate one or several kinds of cytokine such as IL1, IL4,
IL6, IL8, IL10, IFN-g, TGF-b and immune related protein
TLR4 have the potential to promote both humoral and
cellular immune responses. Some ingredients of anti-CVD
herbs might be the candidate adjuvant.
Conclusion
Herbal ingredients and western drugs, as well as their tar-
gets were thoroughly collected in this work. The similari-
ties and the differences between herbal ingredients and
western drugs were deeply explored. From biochemical
property analysis, the biological function of herbal ingredi-
ents’ targets is more complex than that of the targets of
western drugs. Herbal ingredients tend to target enzymes,
factors, regu-lators protein in cytoplasm and nucleus,
while western drugs lean towards targeting the protein of
channels and transporters, receptors in plasma membrane.
From pathway analysis, the signal transduction and
immune system associated signaling pathways, apoptosis
associated pathways are always the most important path-
way for herbal ingredients, however western drugs incline
to regulate vascular smooth muscle contraction associated
pathways. From disease network analysis, herbal ingredi-
ents prefer to regulate the downstream proteins of apopto-
sis associated pathway, while the western drugs incline to
regulate the upstream proteins of VECC related pathways.
According to some statistics, nearly one-third of the top-
selling drugs in the world are nature products or their
derivatives, and nature products are the most consistently
successful source of drug leads [46,47]. Herbal ingredients
may provide some new clues to drugs development for
CVDs. Herbal ingredients may also have the potential to
be used in design of new vaccines.
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